Selective NR2B antagonists

US9221796B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dalton King · Hamden, US
• Lorin A. Thompson, III · Higganum, US
• Jianliang Shi · Furlong, US
• Srinivasan Thangathirupathy · Hosur, IN
• Jayakumar Sankara Warrier · Bengaluru, IN
• Imadul Islam · Hercules, US
• John E. Macor · Guilford, US

Key dates

• Filing date: Jan 5, 2015
• Grant date: Dec 29, 2015
• Expiry date: Jan 5, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.